Unicycive Therapeutics (UNCY) Interest Expenses (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Interest Expenses data on file, last reported at $11.9 million in Q1 2026.

• Quarterly Interest Expenses rose 11762.0% year-over-year to $11.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.9 million (up 6490.0% YoY) and the FY2025 annual result came in at $25.7 million, up 30.51% from the prior year.
• Interest Expenses advanced to $11.9 million in Q1 2026, from -$429000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $229.1 million in Q1 2023 to a low of -$429000.0 in Q4 2025.
• A 5-year average of $23.2 million and a median of $269000.0 in 2022 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses surged 85055.76% — and 2025, when it tumbled 1000.0%.
• Tracing UNCY's Interest Expenses over 5 years: stood at $3000.0 in 2022, then jumped by 533.33% to $19000.0 in 2023, then plunged by 305.26% to -$39000.0 in 2024, then plunged by 1000.0% to -$429000.0 in 2025, then soared by 2865.03% to $11.9 million in 2026.
• The last three Interest Expenses figures came in at $11.9 million (Q1 2026), -$429000.0 (Q4 2025), and $7.5 million (Q3 2025), per Business Quant data.